Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on OPTIBIOTIX HEALTH PLC. We currently have 36 research reports from 2 professional analysts.
|08Feb17 09:30||RNS||Exercise of Warrants and Issue of Equity|
|26Jan17 14:06||RNS||Result of General Meeting|
|18Jan17 07:00||RNS||Appointment of Sales and Marketing Director|
|17Jan17 16:50||RNS||Holding(s) in Company|
|13Jan17 15:44||RNS||Exercise of Option and Issue of Equity|
|11Jan17 10:04||RNS||Exercise of Warrants and Issue of Equity|
|05Jan17 07:00||RNS||Appointment of Commercial Director|
Frequency of research reports
Research reports on
OPTIBIOTIX HEALTH PLC
OPTIBIOTIX HEALTH PLC
Go with your gut
24 Jan 17
OptiBiotix is an early-stage, revenue-generating life sciences business with novel IP surrounding the modulation of the human microbiome. Its technology is focused on tackling worldwide health issues (e.g. obesity, diabetes, high cholesterol and microbial infections), exploiting these large market segments via the c.£200bn functional foods market by partnering with food, health, wellbeing and pharmaceutical companies that have established routes to market. With the microbiome fast becoming a rapidly growing area of interest, OptiBiotix is well positioned to be one of the leaders in this field – a lower-risk entry into the microbiome space compared with pharma plays with higher regulatory and development risk profiles.
05 Oct 16
ACE LIBERTY & STONE PLC (ALSP PZ) | DP POLAND PLC (DPP LN) | FUSIONEX INTERNATIONAL PLC (FXI LN) | GOOCH & HOUSEGO PLC (GHH LN) | KODAL MINERALS PLC (KOD LN) | OPTIBIOTIX HEALTH PLC (OPTI LN) | PARK GROUP (PKG LN) | PREMIER AFRICAN MINERALS LTD (PREM LN) | SAFECHARGE INTL GROUP LTD (SCH LN) | TIME OUT GROUP PLC (TMO LN)
Consistently strong growth at a sensible price
24 Feb 17
In “Alice in Wonderland”, Lewis Carroll tells the story of a girl, who falls through a rabbit hole into a world populated by peculiar, anthropomorphic creatures. Here, Alice crosses swords with the Queen of Hearts, meets the Cheshire Cat and is invited to the "Mad Hatters” tea party, which she subsequently discovers is “stupid”.
Interim results – adhering to international growth strategy
23 Feb 17
Interim results showed a strong performance for Tristel, 6% ahead of its AGM statement on 12 December at which it indicated adjusted pre-tax profits to be no less than £1.6m. Revenues increased by 22% (16% at constant exchange rates – CER or 12% CER excluding the impact of the Australian acquisition) and adjusted pre-tax profits were up 15% to £1.71m. Despite the strong half, we leave our full-year forecasts unchanged, given FX uncertainty and a one-off stocking order in H1 from the NHS, although at current FX rates the risk to our forecasts is considered to be to the upside. However, we raise our target price by 10% to 165p to reflect the solid progress as well as rolling forward our multiples to calendar-adjusted 2017.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
£21m equity raise to accelerate growth
22 Feb 17
Blindly following what others do is often a recipe for disaster. However, when an army of ‘super smart’ fund managers snap-up a big holding in a rapidly expanding small-cap that owns ‘disruptive’ technology addressing multi-$billion markets, then it is usually worth taking note. This is exactly what has happened at Kromek, a next generation radiation detection firm. Having just successfully completed its oversubscribed £20m placing and £1m open offer at 20p/share - supported by esteemed investors such as Gervais Williams at Miton (largest shareholder at 19.0%) and Katie Potts (Herald 5.35%), as well as several others such as Schroders (5.0%) and Killik (4.1%).
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals
N+1 Singer - Anpario - Feed for growth
24 Feb 17
Anpario’s natural animal feed additive product offering is well placed to benefit from the increasing demand for animal protein and tightening regulations around antibiotic use as growth promoters. The group is in a transition phase, building strong commercial relationships with end users, which we believe should benefit the margin. Anpario’s geographical diversity is a key positive and with a strong balance sheet there is potential for acquisitive as well as organic growth. We initiate coverage with a 354p Target Price and a Buy recommendation ahead of FY results on 8th March.